REPORT OVERVIEW:

Antibody Drug Conjugates or (ADCs) is a novel cancer treatment that combines the targeting ability of antibodies with the killing power of chemotherapy. It is mainly composed of a monoclonal antibody (mAb) linked to a highly cytotoxic agent or payload via a synthetic linker.

ADCs function by targeting and attaching to certain tumor cell surface proteins known as antigens. Upon internalization, the attached cytotoxic payload is released into the targeted cell, causing microtubule disruption or DNA damage, resulting in apoptosis or cell death.

ADCs have become an innovative solution to treat various hematological and solid tumor indications due to the benefits associated with them such as selectively killing cancerous cells while sparing healthy cells, easy administration, high efficacy, and cost-effective option as compared to other available immunotherapy products.

Since the first ADC Mylotarg was approved in 2000, so far 13 ADC products have received market approval, including Adcetris, Kadcyla, Enhertu, and, most recently approved, Elahere (Mirvetuximab Soravtansine).

Currently, 314 ADCs are being evaluated in clinical trials, with 15 late-stage candidates expected to receive market approval during the forecast period.

According to Biotech Forecasts, the Global Antibody Drug Conjugates (ADCs) Market was valued at USD 5,270.44 Million in 2021, and it is estimated to reach USD 33,393.98 Million by 2030, registering a CAGR of 18.92% from 2022 to 2030.

Factors that drive the market growth involve, (1) Surging Investment Pertaining to ADCs: Venture capital landscape of ADCs is soaring with high investments. For instance, in May 2022 Tubulis raised  €60 Million in series B, in December 2021 Emergence Therapeutics raised €87M in Series A. Furthermore, in February 2022, Synaffix signed a collaboration deal value of up to  USD 586 million with MacroGenics to develop three next generation ADCs.

(2) The rise in the prevalence of cancer: Increasing cancer patient population is the major factor driving the market growth. According to WHO statistics, cancer was responsible for approximately 10 million deaths worldwide in 2020, and it is anticipated to reach 17 million deaths by 2030.

Other factors that fuel the market growth involve, the surging number of approved products, and rising demand for antibody based therapies. However, the high costs associated with the process, and potential side effects might hamper the market growth.

The report also presents a detailed quantitative analysis of the current market trends and future estimations from 2022 to 2030. The forecasts cover 7 Antigen Types, 8 Products, 4 Applications, and 4 Regions.

The report comes with an associated file covering quantitative data from all numeric forecasts presented in the report, as well as a clinical trial data file.

TOPICS COVERED:

The report covers the following topics:

• Market Drivers, Restraints, and Opportunities
• Porter’s Five Forces Analysis
• Key Developments in ADCs Market
• Market Analysis by Antigen Type, Product, Application, and Region
• Clinical Trials Analysis from 2000 to Q3-2022
• 13 Approved Product Profiles, Financial Overview, and Key Developments
• 20 Company Profiles, ADCs Pipeline, Financial overview, and Key Strategies
• Market analysis and forecast from 2022 to 2030

FORECAST SEGMENTATION:

Market forecasts are provided for each of the following submarkets and their categories:

1- By Antigen Type

• HER2
• CD30
• Nectin-4
• TROP-2
• CD22
• BCMA
• Others

2- By Product

• Kadcyla
• Adcetris
• Enhertu
• Padcev
• Trodelvy
• Polivy
• Besponsa
• Others

3- By Application

• Breast Cancer
• Blood Cancer
• Urothelial Cancer
• Others

4- By Region

• North America: USA, Canada,  Mexico
• Europe: The U.K., Germany, France, Switzerland, Italy, Spain, Rest of Europe
• Asia-Pacific: China, Japan, South Korea, India, Rest of Asia-Pacific
• LAMEA: Brazil, South Africa, Rest of LAMEA